Skip to main content

Lung Dendritic Cells: Targets for Therapy in Allergic Disease

Buy Article:

$68.00 + tax (Refund Policy)

Dendritic cells are crucial in determining the functional outcome of allergen encounter in the lung. Antigen presentation by myeloid DCs leads to Th2 sensitization typical of allergic disease, whereas antigen presentation by plasmacytoid DCs serves to dampen inflammation. It is increasingly clear that DCs have an antigen presenting function beyond sensitisation. DCs therefore constitute a novel target for the development of anti-allergic therapy aimed at the origin of the inflammatory cascade. A careful study of DC biology and of the receptors expressed by lung DCs has provided a framework for the discovery of novel anti-allergic compounds.





Keywords: Airway inflammation; Allergic Disease; Dendritic Cells; Drug Targets; Th2 cells; anti-allergic therapy; dampen inflammation; immune system

Document Type: Research Article

Publication date: 01 August 2008

More about this publication?
  • Current Molecular Medicine is an interdisciplinary journal focused on providing the readership with current and comprehensive reviews on fundamental molecular mechanisms of disease pathogenesis, the development of molecular-diagnosis and/or novel approaches to rational treatment. The reviews should be of significant interest to basic researchers and clinical investigators in molecular medicine. Periodically the journal will invite guest editors to devote an issue on a basic research area that shows promise to advance our understanding of the molecular mechanism(s) of a disease or has potential for clinical applications.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content